Efficacy of pegylated interferon [peginterferon-alfa-2a] on liver fibrosis in co-infected patient with HIV and hepatitis C who failed to active treatment for HCV [hepatitis C virus]. ANRSHC12 Fibrostop.

Trial Profile

Efficacy of pegylated interferon [peginterferon-alfa-2a] on liver fibrosis in co-infected patient with HIV and hepatitis C who failed to active treatment for HCV [hepatitis C virus]. ANRSHC12 Fibrostop.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2013

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Feb 2012 Additional lead trial centre identified, actual initiation date changed from Jul 2003 to Nov 2003 and actual patient number is 52 as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top